B-Cell Chronic Lymphocytic Leukemia
Conditions
Keywords
Chronic lymphocytic leukemia, relapsed, elderly or unfit patients, methylprednisolone, rituximab
Brief summary
The study will test the efficacy rituximab in addition to glucocorticoids for the treatment of B-CLL in elderly or unfit patients.
Detailed description
Patient Population: Pretreated patients with symptomatic B-CLL 18-64 years of age with poor performance status or \>/=65 years of age with any performance status. Treatment: Up-to 4 cycles of glucocorticoid (Methylprednisolone or Dexamethasone) and Rituximab every 21 day. Study Duration: The study period for each subject is expected to be 21 months. Subjects will receive up-to 4 cycles of IV infusion of Rituximab and Glucocorticoid. Maximum duration of treatment is expected to be 6 months. Subjects will complete scheduled visits not later than Study Month 21, thereafter they will enter into the long-term follow-up period. Subjects will be followed every 3 months for disease progression, initiation of subsequent leukemia treatment or survival.
Interventions
DRUGRituximab
Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
DRUGGlucocorticoid
Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
Sponsors
Prof. Dr. Med. Laimonas Griskevicius
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The diagnosis of CD20 positive chronic B lymphocytic leukemia (BCLL) confirmed by biopsy or flow-cytometry. * Previously treated patients with stage Rai I-IV and progressive disease (according to IWCLL 2008 guidelines). Active B-CLL is defined by at least one of the following: At least one of the disease related symptoms: * Constitutional symptoms: * Weight loss \>10% within the previous 6 months; * Fatigue (e.g., WHO performance status \>/=2); * Fever \>/=38C \>/=2 weeks without evidence of infection; * Night sweats for more than 1 month without evidence of infection. * Evidence of progressive marrow failure as manifested by development of, or worsening of, anemia and/or thrombocytopenia * Autoimmune hemolysis and/or thrombocytopenia poorly responsive to corticosteroid therapy. * Massive (i.e., \>/=6 cm bellow left costal margin) or progressive or symptomatic splenomegaly. * Massive lymphadenopathy or conglomerates (i.e., \>/=10 cm in largest diameter) or progressive or symptomatic lymphadenopathy. * Progressive lymphocytosis with an increase \>50% over a 2-month period or an anticipated doubling time of less than 6 months. In patients with initial blood lymphocyte counts of less than 30x10\^9/L LDT should not be used as a single parameter to define treatment indication. Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease is not sufficient for protocol therapy. * Either of the following: * 18 years of age or older with impaired performance status (CIRS \> 6) and /or * 65 years of age or older with any performance status. * Signed informed consent form.
Exclusion criteria
* Intolerance to exogenous protein or known severe reaction to the administration of Rituximab. * Active infection. * Cancer radiotherapy, biological therapy or chemotherapy within 3 weeks prior to Study Day 1. * TBC or fungal infection within the past 6 months even if adequately controlled by treatment. * Severe organ deficiency preventing the participation in the study. * Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1. * Active peptic ulcer. * Inadequately controlled diabetes mellitus. * Suspected or confirmed B-CLL CNS disease. * Known to be HIV positive. * Difficult to control, uncooperative patients. * Allergic disorders in need of chronic glucocorticoid therapy. * Other oncological diseases requiring active treatment (except hormonal therapy). * Pregnancy and breastfeeding. * Patients of reproductive potential who are not using effective methods of contraception.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | 3 months +/- 2 weeks after the last treatment cycle. | Overall response rate (ORR) is defined according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2008) guidelines, as the proportion of patients achieving complete response (CR), CR with minimal residual disease (MRD) negativity (complete molecular remission), nodular partial remission (nPR) and partial response (PR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | up to 12 months | Progression free survival (PFS) will be defined as the interval from entry into the study to disease progression or death. |
| Number of Participants With Adverse Events | 6 months. | Adverse events NCI CTCAE, version 4.0. Hematological toxicity was evaluated according to IWCLL 2008 guidelines. |
| Overall Survival | from date of randomization until the date of death from any cause, assessed up to 100 months | Overall survival (OS) will be defined as the interval from date of randomization until the date of death from any cause, assessed up to 100 months. |
Countries
Lithuania
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| R-HDMP Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
Rituximab: Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
Glucocorticoid: Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion. | 25 |
| Total | 25 |
Baseline characteristics
| Characteristic | R-HDMP |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 25 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Age, Continuous | 73 years |
| Region of Enrollment Lithuania | 25 Participants |
| Sex: Female, Male Female | 18 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 23 / 25 |
| serious Total, serious adverse events | 9 / 25 |
Outcome results
Primary
Overall Response Rate
Overall response rate (ORR) is defined according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2008) guidelines, as the proportion of patients achieving complete response (CR), CR with minimal residual disease (MRD) negativity (complete molecular remission), nodular partial remission (nPR) and partial response (PR).
Time frame: 3 months +/- 2 weeks after the last treatment cycle.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| R-HDMP | Overall Response Rate | 7 Participants |
Secondary
Number of Participants With Adverse Events
Adverse events NCI CTCAE, version 4.0. Hematological toxicity was evaluated according to IWCLL 2008 guidelines.
Time frame: 6 months.
Population: Patient, who experienced any AE - 23.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| R-HDMP | Number of Participants With Adverse Events | 23 Participants |
Secondary
Overall Survival
Overall survival (OS) will be defined as the interval from date of randomization until the date of death from any cause, assessed up to 100 months.
Time frame: from date of randomization until the date of death from any cause, assessed up to 100 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-HDMP | Overall Survival | 68 months |
Secondary
Progression Free Survival
Progression free survival (PFS) will be defined as the interval from entry into the study to disease progression or death.
Time frame: up to 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-HDMP | Progression Free Survival | 11 months |